ArticleFrontiers in neurology2025
Gastrointestinal dysfunction in aneurysmal subarachnoid hemorrhage: prevalence, clinical correlates, and prognostic implications from a 15-year ICU cohort study.
Article in Frontiers in neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Pharmacokinetic and Pharmacodynamic Profiles of Intravenous and Enteral Nimodipine in Patients with Aneurysmal Subarachnoid Hemorrhage: A Scoping Review.Journal of clinical medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Gastrointestinal dysfunction (GID) is increasingly recognized in neurocritical care, but disease-specific epidemiology, associated clinical factors, and outcomes in aneurysmal subarachnoid hemorrhage (aSAH) remain insufficiently characterized. We aimed to quantify the prevalence of GID in patients with aSAH, identify its clinical associations, and evaluate its prognostic implications. Methods: We conducted a 15-year retrospective cohort study involving consecutive adults with aSAH who were admitted to the neurological intensive care unit (NICU) at West China Hospital (24 October 2009-29 June 2024). GID was defined pragmatically as the presence of the following symptoms/signs: gastric residual volume [GRV] ≥ 500 mL on any calendar day after enteral nutrition initiation, gastrointestinal bleeding, or Bristol-defined diarrhea. GID occurrence was modeled using Fine-Gray competing-risk analysis (with in-hospital death as the competing event). In-hospital mortality was analyzed using multivariable logistic regression. Thirty-day survival was described by Kaplan-Meier (KM) curves. Results: Among the 994 patients with aSAH, GID occurred in 44.8% (445/994). Compared to non-GID patients, those with GID had higher admission heart rates and temperature levels, along with a greater proportion having a Hunt-Hess (HH) score ≥4 (43% vs. 20%, Conclusion: In aSAH, GID is common and correlates with neurological severity, autonomic dysregulation, systemic inflammation, and resource use. Although GID is not independently associated with mortality after adjustment, it identifies a high-risk subgroup and supports early, structured gastrointestinal supportive strategies in neurocritical care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.